Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Athersys, Inc. (ATHX : NSDQ)
 
 • Company Description   
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).

Number of Employees: 104

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.26 Daily Weekly Monthly
20 Day Moving Average: 5,378,866 shares
Shares Outstanding: 251.97 (millions)
Market Capitalization: $65.66 (millions)
Beta: -1.29
52 Week High: $1.81
52 Week Low: $0.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -52.76% -48.28%
12 Week -71.99% -68.52%
Year To Date -71.13% -64.73%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3201 CARNEGIE AVENUE
-
CLEVELAND,OH 44115
USA
ph: 216-431-9900
fax: 216-361-9495
ir@athersys.com http://www.athersys.com
 
 • General Corporate Information   
Officers
Daniel A. Camardo - Chief Executive Officer and Director
Ismail Kola - Chairman and Director
Ivor Macleod - Chief Financial Officer
John J. Harrington - Executive Vice President; Chief Scientific Officer
Hardy TS Kagimoto - Director

Peer Information
Athersys, Inc. (CORR.)
Athersys, Inc. (RSPI)
Athersys, Inc. (CGXP)
Athersys, Inc. (BGEN)
Athersys, Inc. (GTBP)
Athersys, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04744L106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 251.97
Most Recent Split Date: (:1)
Beta: -1.29
Market Capitalization: $65.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.77%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 303.32%
ROE
03/31/22 - -323.22
12/31/21 - -301.29
09/30/21 - -268.18
ROA
03/31/22 - -120.69
12/31/21 - -125.17
09/30/21 - -126.10
Current Ratio
03/31/22 - 1.00
12/31/21 - 1.54
09/30/21 - 2.10
Quick Ratio
03/31/22 - 1.00
12/31/21 - 1.54
09/30/21 - 2.10
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -981.52
12/31/21 - -1,576.99
09/30/21 - -1,442.59
Book Value
03/31/22 - 0.00
12/31/21 - 0.07
09/30/21 - 0.13
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©